See more : Nanovation Microtech, Inc. (NANN) Income Statement Analysis – Financial Results
Complete financial analysis of Zymeworks Inc. (ZYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymeworks Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FDG Kinetic Limited (0378.HK) Income Statement Analysis – Financial Results
- GA eXpress, Inc. (GAEX) Income Statement Analysis – Financial Results
- Experian plc (EXPGF) Income Statement Analysis – Financial Results
- Tilray Brands, Inc. (2HQ.DE) Income Statement Analysis – Financial Results
- CONTAINE TECHNOLOGIES LIMITED (CONTAINE.BO) Income Statement Analysis – Financial Results
Zymeworks Inc. (ZYME)
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.01M | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M | 51.76M | 11.01M | 9.66M | 1.67M |
| Cost of Revenue | 142.99M | 208.70M | 199.54M | 170.90M | 117.10M | 56.93M | 41.14M | 35.55M | 24.40M | 10.47M |
| Gross Profit | -66.98M | 203.78M | -172.86M | -131.95M | -87.55M | -3.91M | 10.62M | -24.54M | -14.74M | -8.80M |
| Gross Profit Ratio | -88.11% | 49.40% | -647.90% | -338.75% | -296.34% | -7.37% | 20.51% | -222.93% | -152.62% | -527.13% |
| Research & Development | 143.62M | 208.60M | 199.75M | 168.53M | 115.90M | 56.68M | 41.75M | 36.82M | 24.65M | 12.62M |
| General & Administrative | 70.45M | 73.36M | 42.56M | 57.89M | 64.18M | 29.46M | 18.55M | 12.55M | 5.22M | 3.95M |
| Selling & Marketing | -46.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 70.40M | 73.36M | 42.56M | 57.89M | 64.18M | 29.46M | 18.55M | 12.55M | 5.22M | 3.95M |
| Other Expenses | -142.94M | 4.71M | 3.27M | 7.35M | 5.28M | -1.26M | -964.00K | -1.27M | -251.00K | -2.15M |
| Operating Expenses | 71.08M | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M | 59.22M | 48.11M | 29.62M | 14.42M |
| Cost & Expenses | 214.07M | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M | 59.22M | 48.11M | 29.62M | 14.42M |
| Interest Income | 19.71M | 3.60M | 1.97M | 5.70M | 6.02M | 2.64M | 743.00K | 308.00K | 324.00K | 116.00K |
| Interest Expense | 0.00 | 3.60M | 0.00 | 0.00 | 0.00 | 166.00K | 892.00K | 950.00K | 18.00K | 9.00K |
| Depreciation & Amortization | 17.31M | 12.00M | 9.58M | 10.28M | 7.33M | 3.63M | 2.74M | 1.03M | 494.00K | 412.00K |
| EBITDA | -129.96M | 147.24M | -206.09M | -177.17M | -143.19M | -30.76M | -6.08M | -36.26M | -18.62M | -12.34M |
| EBITDA Ratio | -170.97% | 31.64% | -808.22% | -481.29% | -506.92% | -62.48% | -11.45% | -329.37% | -198.16% | -749.28% |
| Operating Income | -138.05M | 130.53M | -215.63M | -187.47M | -151.30M | -33.13M | -9.00M | -37.86M | -19.96M | -12.75M |
| Operating Income Ratio | -181.62% | 31.64% | -808.22% | -481.29% | -512.12% | -62.48% | -17.38% | -343.94% | -206.63% | -763.35% |
| Total Other Income/Expenses | 18.81M | 4.71M | 3.27M | 7.35M | 5.28M | -1.02M | -964.00K | -1.02M | 824.00K | -194.00K |
| Income Before Tax | -119.24M | 135.23M | -212.36M | -180.12M | -146.02M | -34.39M | -9.96M | -38.88M | -19.14M | -12.94M |
| Income Before Tax Ratio | -156.87% | 32.79% | -795.95% | -462.43% | -494.24% | -64.85% | -19.25% | -353.20% | -198.10% | -774.97% |
| Income Tax Expense | -568.00K | 10.89M | -516.00K | 429.00K | -582.00K | 2.17M | 444.00K | -5.08M | 34.00K | -284.00K |
| Net Income | -118.67M | 124.34M | -211.84M | -180.55M | -145.44M | -36.56M | -10.41M | -33.81M | -19.17M | -12.94M |
| Net Income Ratio | -156.13% | 30.14% | -794.01% | -463.54% | -492.27% | -68.95% | -20.10% | -307.10% | -198.45% | -774.97% |
| EPS | -1.72 | 1.91 | -4.06 | -3.58 | -3.83 | -1.26 | -0.49 | -1.72 | -0.97 | -0.65 |
| EPS Diluted | -1.72 | 1.90 | -4.06 | -3.58 | -3.83 | -1.26 | -0.49 | -1.72 | -0.97 | -0.65 |
| Weighted Avg Shares Out | 68.86M | 65.19M | 52.13M | 50.38M | 37.97M | 29.01M | 21.25M | 19.70M | 19.84M | 19.84M |
| Weighted Avg Shares Out (Dil) | 68.86M | 65.25M | 52.13M | 50.38M | 38.02M | 29.09M | 21.32M | 19.70M | 19.84M | 19.84M |
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate...
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced, with Jazz Pharmaceuticals, that...
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in...
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus...
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer...
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago.
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate...
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for...
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient...
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report...
Source: https://incomestatements.info
Category: Stock Reports